BARDA Stakeholder Portal
aspr U.S. Department of Health & Human Services
Administration for Strategic Preparedness and Response
US Flag An official website of the United States government Here’s how you know
×

Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites

Project NextGen

Enhancing our preparedness for COVID-19 strains and variants

Strategic Plan

Fortifying The Nation's Health Security

Partner with Us

Learn about BARDA's funding opportunities

ACTIVE OPPORTUNITY SPOTLIGHT

FLEXIBLE AND STRATEGIC THERAPEUTICS (FASTx) PROGRAM

The FASTx program aims to transform antiviral therapy by developing rapidly adaptable platforms to combat viral threats. The program will leverage cutting-edge technology such as nucleic acid-expressed mAbs, single domain antibodies, double-stranded RNA-mediated interference (RNAi), and clustered regular interspaced short palindromic repeat-associated proteins (CRISPR-Cas), which can be rapidly manufactured in response to emerging viral threats.

LEARN MORE
image of virus

BARDA Programs

The mission of the Biomedical Advanced Research and Development Authority (BARDA) is to develop medical countermeasures that address the public health and medical consequences of chemical, biological, radiological, and nuclear (CBRN) accidents, incidents and attacks, pandemic influenza, and emerging infectious diseases.

We accomplish this critical mission through these key activities

BARDA Seal
Chemical, Biological, Radiological & Nuclear
(CBRN)

CBRN helps innovators develop promising MCMs from preclinical development to clinical trials and manufacturing scale-up to FDA approval.

CBRN Programs
  • Antimicrobials
  • Antivirals & Antitoxins
  • Burn & Blast MCMs
  • Chemical MCMs
  • Radiological & Nuclear MCMs
  • Vaccines
Learn More
Clinical Development
(DCD)

DCD provides clinical development and operations expertise to BARDA programs. DCD also manages the Clinical Studies Network (CSN) that develops clinical protocols for evaluation and testing in FDA-regulated trials.

Learn More
Contract Management and Acquisition
(CMA)

CMA provides flexible and innovative acquisition solutions in support of BARDA’s mission. CMA strives to enhance the U.S. government’s contracting capabilities to respond quickly to both known and emerging public health threats.

Learn More
Detection, Diagnostics, and Devices Infrastructure
(DDDI)

DDDI invests in diagnostics and devices across the spectrum of advanced research and development, stockpiling, and domestic manufacturing capacity expansion.

Learn More
Nonclinical Development
(DNCD)

DNCD provides nonclinical models, tools, and expertise to advance MCM development. DNCD provides expertise and laboratory capacity to establish and share nonclinical models, conduct appropriate nonclinical studies to support FDA approval, and evaluate potential MCM candidates prior to BARDA investment.

Learn More
Research, Innovation & Ventures
(DRIVe)

DRIVe works to accelerate the development and availability of transformative technologies and approaches to protect Americans from health security threats. DRIVe aims to de-risk the most promising technologies and capabilities.

DRIVe Programs
  • DRIVe’s R&D Programs
  • Ecosystem Programs
Learn More
Influenza & Emerging Infectious Diseases
(IEID)

Influenza & EID invests in advanced research and development, manufacturing capacity, and procurement of MCMs to protect the nation from pandemic influenza and other emerging infectious diseases.

Influenza & EID Programs
  • Pandemic Vaccines and Adjuvants
  • Therapeutics
  • Vacccines Development
Learn More
Pharmaceutical Countermeasures and Infrastructure
(PCI)

PCI provides expertise to strengthen the nation’s ability to manufacture, distribute, administer, and scale production of lifesaving MCMs.

Learn More
Regulatory & Quality Affairs
(RQA)

RQA ensures that BARDA-supported MCMs are safe, effective, and in compliance with relevant and current laws, regulations, and guidelines by providing technical expertise and innovative regulatory and policy approaches.

RQA Programs
  • Regulatory Affairs
  • Quality Affairs
  • Regulatory Operations
Learn More

Special Initiatives

BARDA invests in innovative projects across our portfolio, including promising technologies, platforms, and programs. We launch and support efforts designed to accelerate and foster smaller new projects.

Prism

Sepsis

Sprint